1
Active ETFs & REITs Could Be a Match Made in Heaven
Aaron Levitt
|
Using an active strategy via an ETF could prove to be the best...
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
| Ticker | Mutual Fund | Exposure | % of Shares Owned |
|---|---|---|---|
| FBDIX | Franklin Biotechnology Discovery A | Tekmira Pharmaceuticals (TKMR) | 3.15% |
| SHSAX | BlackRock Health Sciences Opps Inv A | Tekmira Pharmaceuticals (TKMR) | 1.53% |
| FBIOX | Fidelity Select Biotechnology Portfolio | NewLink Genetics Corp (NLNK) | 5.93% |
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Receive email updates about best performers, news, CE accredited webcasts and more.
Aaron Levitt
|
Using an active strategy via an ETF could prove to be the best...
Justin Kuepper
|
Let's look at how investors can hedge against interest rate risk with active...
Jayden Sangha
|
In this article, we will take a closer look at some of the...
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Shares of Tekmira Pharmaceuticals (TKMR) have been surging as the company is now in clinical trials to create a drug for the virus. The company has been given approval by the FDA to give its TKM-Ebola drug to subjects “with confirmed or suspected Ebola virus infections.”
The recent U.S. case of Ebola in the U.S. also now has pharmaceutical companies racing to create a vaccine for the virus.
The companies involved in the treatment or vaccination of the virus range from small biotech companies to pharma giants like GlaxoSmithKline (GSK).
| Ticker | Mutual Fund | Exposure | % of Shares Owned |
|---|---|---|---|
| FBDIX | Franklin Biotechnology Discovery A | Tekmira Pharmaceuticals (TKMR) | 3.15% |
| SHSAX | BlackRock Health Sciences Opps Inv A | Tekmira Pharmaceuticals (TKMR) | 1.53% |
| FBIOX | Fidelity Select Biotechnology Portfolio | NewLink Genetics Corp (NLNK) | 5.93% |
There are several mutual funds that offer specific exposure to these industries including the funds listed above.
Receive email updates about best performers, news, CE accredited webcasts and more.
Aaron Levitt
|
Using an active strategy via an ETF could prove to be the best...
Justin Kuepper
|
Let's look at how investors can hedge against interest rate risk with active...
Jayden Sangha
|
In this article, we will take a closer look at some of the...
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Receive email updates about best performers, news, CE accredited webcasts and more.
Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.